Vanda Pharmaceuticals Inc.

VNDANASDAQHealthcare● Active

$5.97

$-0.07(-1.08%)

Market Cap$358708627

P/E Ratio—

52W High$9.94

52W Low$4.14

Avg Volume1.4M

Open$6.11

Beta0.60

Insider Trades Ownership Employees

Vanda Pharmaceuticals Inc. (VNDA) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · VNDA · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.57

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 36%Active transactions only · RSU vesting excluded64% Sell ↓

Vanda Pharmaceuticals Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

VNDA insider buying and selling by quarter

VNDA insider selling · VNDA insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

1.0M513K0

2024 Q2

2024 Q3

2024 Q4

2025 Q1

2025 Q2

2025 Q3

2026 Q1

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · VNDA ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

VNDA executive sell shares · VNDA board member insider trading · VNDA insider trading SEC filing

Showing 75 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
May 18, 2026	Mitchell Stephen Ray Director	Gift	25,836	—	—	71,246	Form 4
Apr 22, 2026	Duncan Charles Cliff Director	Award	57,101	—	—	57,101	Form 4
Mar 2, 2026	Williams Timothy SVP & General Counsel	Sale	42,434	$8.27	$351K	377,450	Form 4
Mar 2, 2026	Moran Kevin Patrick SVP, CFO & Treasurer	Sale	42,442	$8.27	$351K	411,380	Form 4
Mar 2, 2026	Wijkstrom Joakim SVP, Chief Marketing Officer	Sale	30,800	$8.27	$255K	333,469	Form 4
Mar 2, 2026	Polymeropoulos Mihael Hristos Director	Sale	156,235	$8.17	$1.28M⚡	2,704,496	Form 4
Mar 2, 2026	Birznieks Gunther SVP, Business Development	Sale	42,431	$8.27	$351K	494,197	Form 4
Feb 23, 2026	Honore Tage Director	Sale	30,000	$8.03	$241K	93,469	Form 4
Feb 18, 2026	Wijkstrom Joakim SVP, Chief Marketing Officer	Award	125,000	—	—	364,269	Form 4
Feb 18, 2026	Birznieks Gunther SVP, Business Development	Award	125,000	—	—	536,628	Form 4
Feb 18, 2026	Williams Timothy SVP & General Counsel	Award	125,000	—	—	419,884	Form 4
Feb 18, 2026	Moran Kevin Patrick SVP, CFO & Treasurer	Award	125,000	—	—	453,822	Form 4
Feb 18, 2026	Polymeropoulos Mihael Hristos Director	Award	525,000	—	—	2,860,731	Form 4
Aug 7, 2025	Polymeropoulos Mihael Hristos Director	Purchase	10,000	$4.15	$42K	2,335,731	Form 4
Jun 13, 2025	Mitchell Stephen Ray Director	Sale	7,000	$4.59	$32K	97,082	Form 4
Jun 5, 2025	Mitchell Stephen Ray Director	Award	59,225	—	—	104,082	Form 4
Jun 5, 2025	Chrousos Phaedra Director	Award	59,225	—	—	123,350	Form 4
Jun 5, 2025	DUGAN RICHARD W Director	Award	59,225	—	—	177,454	Form 4
Jun 5, 2025	Honore Tage Director	Award	59,225	—	—	123,469	Form 4
Jun 5, 2025	Ward Anne Sempowski Director	Award	59,225	—	—	119,067	Form 4
May 21, 2025	Polymeropoulos Mihael Hristos Director	Purchase	481	$4.39	$2K	2,325,731	Form 4
May 21, 2025	Polymeropoulos Mihael Hristos Director	Purchase	9,519	$4.40	$42K	2,325,250	Form 4
May 16, 2025	Polymeropoulos Mihael Hristos Director	Purchase	20,000	$4.22	$84K	2,315,731	Form 4
Mar 6, 2025	Polymeropoulos Mihael Hristos Director	Purchase	5,000	$5.01	$25K	2,295,731	Form 4
Mar 6, 2025	Polymeropoulos Mihael Hristos Director	Purchase	5,000	$5.02	$25K	2,290,731	Form 4

Mitchell Stephen Ray

Director

Gift

Date

May 18

25,836

Price

—

Value

—

View Form 4 on SEC.gov

Duncan Charles Cliff

Director

Award

Date

Apr 22

57,101

Price

—

Value

—

View Form 4 on SEC.gov

Williams Timothy

SVP & General Counsel

Sale

Date

Mar 2

42,434

Price

$8.27

Value

$351K

View Form 4 on SEC.gov

Moran Kevin Patrick

SVP, CFO & Treasurer

Sale

Date

Mar 2

42,442

Price

$8.27

Value

$351K

View Form 4 on SEC.gov

Wijkstrom Joakim

SVP, Chief Marketing Officer

Sale

Date

Mar 2

30,800

Price

$8.27

Value

$255K

View Form 4 on SEC.gov

Polymeropoulos Mihael Hristos

Director

Sale

Date

Mar 2

156,235

Price

$8.17

Value

$1.28M ⚡

View Form 4 on SEC.gov

Birznieks Gunther

SVP, Business Development

Sale

Date

Mar 2

42,431

Price

$8.27

Value

$351K

View Form 4 on SEC.gov

Honore Tage

Director

Sale

Date

Feb 23

30,000

Price

$8.03

Value

$241K

View Form 4 on SEC.gov

Wijkstrom Joakim

SVP, Chief Marketing Officer

Award

Date

Feb 18

125,000

Price

—

Value

—

View Form 4 on SEC.gov

Birznieks Gunther

SVP, Business Development

Award

Date

Feb 18

125,000

Price

—

Value

—

View Form 4 on SEC.gov

Williams Timothy

SVP & General Counsel

Award

Date

Feb 18

125,000

Price

—

Value

—

View Form 4 on SEC.gov

Moran Kevin Patrick

SVP, CFO & Treasurer

Award

Date

Feb 18

125,000

Price

—

Value

—

View Form 4 on SEC.gov

Polymeropoulos Mihael Hristos

Director

Award

Date

Feb 18

525,000

Price

—

Value

—

View Form 4 on SEC.gov

Polymeropoulos Mihael Hristos

Director

Purchase

Date

Aug 7

10,000

Price

$4.15

Value

$42K

View Form 4 on SEC.gov

Mitchell Stephen Ray

Director

Sale

Date

Jun 13

7,000

Price

$4.59

Value

$32K

View Form 4 on SEC.gov

Mitchell Stephen Ray

Director

Award

Date

Jun 5

59,225

Price

—

Value

—

View Form 4 on SEC.gov

Chrousos Phaedra

Director

Award

Date

Jun 5

59,225

Price

—

Value

—

View Form 4 on SEC.gov

DUGAN RICHARD W

Director

Award

Date

Jun 5

59,225

Price

—

Value

—

View Form 4 on SEC.gov

Honore Tage

Director

Award

Date

Jun 5

59,225

Price

—

Value

—

View Form 4 on SEC.gov

Ward Anne Sempowski

Director

Award

Date

Jun 5

59,225

Price

—

Value

—

View Form 4 on SEC.gov

Polymeropoulos Mihael Hristos

Director

Purchase

Date

May 21

481

Price

$4.39

Value

$2K

View Form 4 on SEC.gov

Polymeropoulos Mihael Hristos

Director

Purchase

Date

May 21

9,519

Price

$4.40

Value

$42K

View Form 4 on SEC.gov

Polymeropoulos Mihael Hristos

Director

Purchase

Date

May 16

20,000

Price

$4.22

Value

$84K

View Form 4 on SEC.gov

Polymeropoulos Mihael Hristos

Director

Purchase

Date

Mar 6

5,000

Price

$5.01

Value

$25K

View Form 4 on SEC.gov

Polymeropoulos Mihael Hristos

Director

Purchase

Date

Mar 6

5,000

Price

$5.02

Value

$25K

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 3

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About VNDA insider trading

VNDA insider trades

Vanda Pharmaceuticals Inc. (VNDA) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Polymeropoulos Mihael Hristos (Director), Mitchell Stephen Ray (Director), Williams Timothy (SVP & General Counsel). Over the past 12 months, 5 insiders have filed transactions with the SEC. VNDA insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Vanda Pharmaceuticals Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

VNDA insider trading · 5 questions

The insiders of Vanda Pharmaceuticals Inc. (VNDA) include executives and directors such as Polymeropoulos Mihael Hristos (Director), Mitchell Stephen Ray (Director), Williams Timothy (SVP & General Counsel), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

VNDA board member insider tradingwho are VNDA insidersVNDA insider rosterVanda Pharmaceuticals Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026